Stewart AK, Dimopoulos MA, Masszi T, ?pi?ka I, Oriol A, Hájek R, Rosiñol L, Siegel DS, Niesvizky R, Jakubowiak AJ, et al. Health-related quality-of-life results from the open-label, randomized, phase III ASPIRE trial evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patientswith relapsed multiple myeloma. Journal of Clinical Oncology [Internet]. 2016;34(32):3921 - 3930.